I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

Compass Pathways (NASDAQ:CMPS) shares rose nearly 9% premarket on Friday after the biotechnology company priced a securities offering to raise up to $353M. The company is offering ~24.01M American ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass.

Franklin Resources Inc. boosted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS – Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the ...

With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...